IDNG Update: already small Float will be reduced; various subsidies with improved revenues! OS 542M 02/06/2019; Unrestricted 287M
SEC Reporting/Audited Financials
Revenues in the pharmaceutical and medical device business unit are expected to improve as market acceptance of our products increases and we begin sales of our SANDD medical devices. Additionally, net profits are expected to improve as the Company’s pharmaceutical sales become more weighted to its branded generics which offer lower discounts than the discounts offered by the Company for its highly competitive “special” pharmaceuticals and require significantly lower operating costs. Additionally, our medical devices are being offered for sale at very attractive profit margins. https://www.otcmarkets.com/filing/conv_pdf?id=13238157&guid=Q_ZtUqe4gPkDF3h
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.